
Opinion|Videos|February 10, 2025
The Economic Impact of Biosimilars
Panelists discuss how biosimilars have significantly reduced health care costs in the US, with health care systems experiencing significant savings across various therapeutic areas. These cost reductions improve treatment affordability and patient access, with potential cumulative savings in 2025.
Advertisement
Video content above is prompted by the following:
- Biosimilars have been shown to reduce costs to the US health system overall. What kind of savings are you seeing in your health system since fully implementing biosimilars?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Government Shutdown Could Disrupt Health Care Access
2
FDA Approves Remibrutinib for Chronic Spontaneous Urticaria
3
White House, Pfizer Reach Agreement on Drug Discounts; Trump Announces TrumpRx
4
UC Davis Pharmacy Residents Conduct Impactful Research on Medication Management, Patient Care: Jeremiah J. Duby, PharmD, BCPS, BCCCP
5